The primary purpose of Hasumi LLC is to manage, fund, conduct and support scientific research in connection with finding a cure for various forms of cancer, particularly with the use of immunotherapy. Its mission also is to develop a highly sophisticated database and network system for the collection and dissemination of valuable data from cancer research and treatment throughout the world.

The recent changes in immunotherapy are remarkable. They represent many impressive steps by investigators in the field of cancer research. Some of the most remarkable advances during the last decade have occurred in the development of cancer vaccines. Getting the body's own immune system to recognize and destroy the cancer cell is pivotal. Furthermore, the delineation of the potential uses of dendritic cells has opened a new world of tremendous possibilities in terms of immunotherapy and new alternative cancer treatments. These efforts to develop effective cancer vaccines and utilize the body's immune system to fight cancer will expand the knowledge base necessary to save and improve lives of cancer patients throughout the world.

Generally, cancer vaccines are considered appropriate only for very high risk groups after conventional treatments have failed. This makes it difficult in stage III or IV patients to improve "Quality of Life (QOL)" status or to extend life expectancy of these terminally ill patients. We would like to change this by showing people the importance and amazing potential of cancer vaccines to yield good outcomes while preserving QOL.

It is our hope that cancer vaccines will be rapidly developed throughout the world and be recognized as a key part of cancer therapy. Ultimately, these efforts will lead to better cancer patient care and prevention in the 21st century. The resulting new cancer vaccines will improve lives, lessen suffering among cancer patients, and be a cornerstone in the battle against cancer.

Currently, we support and mange the Hasumi International Research Foundation to develop advance cancer immunotherapy/vaccines, including organizing International Cancer Vaccine Symposia. We have developed adjuvant, patented in the United States, India and Russia. We also have a patent with the Dendritic-Cell based therapeutic vaccines, and we are looking for possible licensee partners for these patents.